文献速递泌尿系结石

新型磺酸涂层输尿管支架可减少结壳并改善耐受性:一项随机试验

A novel ureteric stent coating reduces encrustation and improves tolerability in a randomised trial.
PubMed 文献 · BJU Int · 2026-10-09

在德国两个泌尿中心开展的前瞻性随机对照试验中,100例因泌尿系结石需置入输尿管支架的患者随机分组,所有患者使用相同支架(6 F/28 cm),干预组支架带有新型共价涂层。最终95例纳入主要终点分析,涂层支架组平均结壳重量降低49.7%,下尿路症状增加减少53.8%,需抗菌治疗比例显著更低(7.1% vs 31.8%)。

要点

  • 涂层支架平均结壳重量较标准支架降低49.7%(均差22.8 mg,95%CI 2.4-43.2;P=0.006)。
  • 涂层支架组下尿路症状增加减少53.8%(Δ3.6 vs Δ7.8;P=0.002)。
  • 涂层支架组需抗菌治疗比例显著更低(7.1% vs 31.8%,P=0.02)。

核心结论

  • 新型磺酸涂层输尿管支架较标准支架显著减少结壳并改善生活质量。

研究设计与样本

  • 前瞻性随机对照试验,2022年4月至2025年3月在德国两个泌尿中心开展。
  • 共100例因泌尿系结石需置入输尿管支架的患者随机分为干预组和对照组。
  • 所有患者使用相同支架(6 F/28 cm),干预组支架带有新型共价涂层。
  • 支架在30天后二次结石治疗时取出,随后评估结壳重量。
  • 最终95例纳入主要终点分析。

主要发现

  • 涂层支架平均结壳重量降低49.7%(均差22.8 mg,95%CI 2.4-43.2;P=0.006)。
  • 涂层支架组下尿路症状增加减少53.8%(Δ3.6 [95%CI 1.3-6] vs Δ7.8 [95%CI 2.8-12.8];P=0.002)。
  • 轻度体力活动改善33.9%(均差0.76,95%CI 0.08-1.44;P=0.046)。
  • 涂层支架组需抗菌治疗比例显著更低(7.1% vs 31.8%,P=0.02;OR 6.1,95%CI 1.11-33.1)。
  • 涂层支架组疲劳和乏力症状显著更少(均差0.67,95%CI 0.02-1.32;P=0.03)。

临床怎么用

  • 对于需留置输尿管支架的泌尿系结石患者,可考虑使用新型磺酸涂层支架以减少结壳和改善症状。
  • 涂层支架可能降低抗菌治疗需求,但需结合患者具体情况和成本效益综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of a novel sulfonic acid-coated ureteric stent on encrustation and quality of life in patients with urolithiasis. PATIENTS AND METHODS: A prospective, randomised, controlled trial was conducted between April 2022 and March 2025 at two urological centres in Germany. In all, 100 patients requiring ureteric stenting due to urolithiasis were randomised into intervention and control groups. All patients received identical stents (6 F/28 cm); the stent in the intervention group incorporated a novel covalent coating. Stents were removed after 30 days during secondary stone treatment, followed by the encrustation weight assessment. Symptoms associated with the ureteric stent and quality of life were evaluated using the Ureteric Stent Symptom Questionnaire 7 days after stent placement and 7 days after stent removal. RESULTS: The final analysis included 95 patients assessed for the primary endpoint. Coated stents showed a 49.7% reduction in mean encrustation weight (mean difference 22.8 mg, 95% confidence interval [CI] 2.4-43.2; P = 0.006). The increase in lower urinary tract symptoms was 53.8% less in the coated-stent group (Δ3.6 [95% CI 1.3-6] vs Δ7.8 [95% CI 2.8-12.8]; P = 0.002). Light physical activities improved by 33.9% (mean difference 0.76, 95% CI 0.08-1.44; P = 0.046), and the need for antimicrobial therapy was significantly lower for coated stents (7.1% vs 31.8%, P = 0.02; odds ratio 6.1, 95% CI 1.11-33.1). Additionally, patients in the coated-stent group reported significantly less fatigue and exhaustion symptoms (mean difference 0.67, 95% CI 0.02-1.32; P = 0.03). CONCLUSION: The novel sulfonic acid coating demonstrated significant benefits over standard ureteric stents by reducing encrustation and improving quality of life.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vistunov N, Popeneciu IV, Kram W, et al. A novel ureteric stent coating reduces encrustation and improves tolerability in a randomised trial. BJU Int. 2026. PMID: 42852578. doi:10.1111/bju.70487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。